Celularity Analyst Ratings
Celularity Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/30/2023 | 138.1% | HC Wainwright & Co. | $15 → $2.5 | Maintains | Buy |
| 12/22/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 09/12/2022 | 376.19% | Morgan Stanley | $8 → $5 | Maintains | Equal-Weight |
| 08/25/2022 | 1328.57% | Alliance Global Partners | → $15 | Initiates Coverage On | → Buy |
| 08/23/2022 | 471.43% | Truist Securities | $10 → $6 | Maintains | Hold |
| 06/22/2022 | 1328.57% | HC Wainwright & Co. | → $15 | Initiates Coverage On | → Buy |
| 04/06/2022 | — | Truist Securities | Downgrades | Buy → Hold | |
| 01/28/2022 | 757.14% | Oppenheimer | → $9 | Initiates Coverage On | → Outperform |
| 11/24/2021 | 757.14% | Morgan Stanley | → $9 | Initiates Coverage On | → Equal-Weight |
| 10/19/2021 | 1042.86% | Truist Securities | → $12 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年1月30日 | 138.1% | HC Wainwright公司 | $15→$2.5 | 維護 | 買 |
| 2022年12月22日 | - | 奧本海默 | 評級下調 | 超越→表現 | |
| 09/12/2022 | 376.19% | 摩根士丹利 | $8→$5 | 維護 | 等重 |
| 2022年08月25日 | 1328.57% | 聯盟全球合作夥伴 | →$15 | 開始承保 | →購買 |
| 2022年08月23日 | 471.43% | Truist證券 | $10→$6 | 維護 | 保持 |
| 2022/06/22 | 1328.57% | HC Wainwright公司 | →$15 | 開始承保 | →購買 |
| 04/06/2022 | - | Truist證券 | 評級下調 | 購買→Hold | |
| 2022年01月28日 | 757.14% | 奧本海默 | →$9 | 開始承保 | →跑贏大盤 |
| 2021年11月24日 | 757.14% | 摩根士丹利 | →$9 | 開始承保 | →等重 |
| 10/19/2021 | 1042.86% | Truist證券 | →$12 | 開始承保 | →購買 |
What is the target price for Celularity (CELU)?
Celularity(CELU)的目標價是多少？
The latest price target for Celularity (NASDAQ: CELU) was reported by HC Wainwright & Co. on January 30, 2023. The analyst firm set a price target for $2.50 expecting CELU to rise to within 12 months (a possible 138.10% upside). 7 analyst firms have reported ratings in the last year.
賽樂樂(納斯達克代碼：CELU)的最新目標價是由HC Wainwright&Co.於2023年1月30日報道的。這家分析公司將目標價定為2.5美元，預計CELU將在12個月內上漲(漲幅可能為138.10)。去年有7家分析公司公佈了評級。
What is the most recent analyst rating for Celularity (CELU)?
分析師對Celularity(CELU)的最新評級是多少？
The latest analyst rating for Celularity (NASDAQ: CELU) was provided by HC Wainwright & Co., and Celularity maintained their buy rating.
凱樂力士(納斯達克代碼：CELU)的最新分析師評級由HC Wainwright&Co.提供，賽樂力士維持買入評級。
When is the next analyst rating going to be posted or updated for Celularity (CELU)?
Celularity(CELU)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celularity, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celularity was filed on January 30, 2023 so you should expect the next rating to be made available sometime around January 30, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公開財務報表，與Celulity的高管和客戶交談，以及收聽收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Celulity的最後一次評級是在2023年1月30日提交的，所以你應該預計下一次評級將在2024年1月30日左右的某個時候提供。
Is the Analyst Rating Celularity (CELU) correct?
分析師對Celularity(CELU)的評級正確嗎？
While ratings are subjective and will change, the latest Celularity (CELU) rating was a maintained with a price target of $15.00 to $2.50. The current price Celularity (CELU) is trading at is $1.05, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Celulality(CELU)評級保持不變，目標價在15.00美元至2.50美元之間。Celularity(Celu)目前的交易價格為1.05美元，超出了分析師的預測區間。